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Abstract
Drug eluting coatings that can direct the host tissue response to implanted medical devices have
the potential to ameliorate both the medical and financial burden of complications from
implantation. However, because many drugs useful in this arena are biologic in nature, a paucity
of delivery strategies for biologics, including growth factors, currently limits the control that can
be exerted on the implantation environment. Layer-by-Layer (LbL) polyelectrolyte multilayer
films are highly attractive as ultrathin biologic reservoirs, due to conformal coating of difficult
geometries, aqueous processing likely to preserve fragile protein function, and tenability of
incorporation and release profiles. Herein, we describe the first LbL films capable of microgram-
scale release of the biologic Bone Morphogenetic Protein 2 (BMP-2), which is capable of
directing the host tissue response to create bone from native progenitor cells. Ten micrograms of
BMP-2 are released over a period of two weeks in vitro; less than 1% is released in the first 3
hours (compared with commercial collagen matrices which can release up to 60% of BMP-2, too
quickly to induce differentiation). BMP-2 released from LbL films retains its ability to induce
bone differentiation in MC3T3 E1S4 preosteoblasts, as measured by induction of alkaline
phosphatase and stains for calcium (via Alizarin Red) and calcium matrix (via Von Kossa). In
vivo, BMP-2 film coated scaffolds were compared with film coated scaffolds lacking BMP-2.
BMP-2 coatings implanted intramuscularly were able to initiate host progenitor cells to
differentiate into bone, which matured and expanded from four to nine weeks as measured by
MicroCT and histology. Such LbL films represent new steps towards controlling and tuning host
response to implanted medical devices, which may ultimately increase the success of implanted
devices, provide alternative new approaches toward bone wound healing, and lay the foundation
for development of a multi-therapeutic release coating.
1. Introduction
Although protein and peptide based therapeutics represent 13% of total pharma sales and a
growing fraction of approved new therapies in the US [1], several problems still remain in
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biologic drug delivery, including a paucity of strategies for release of bioactive molecules
from implanted medical devices. The success of these life-saving devices, including
orthopaedic implants and cardiovascular devices, is critically linked to host tissue response,
with failure resulting in poor patient outcomes. Complications from orthopaedic hip
implants alone amass $1 billion per year in losses in the US [2]. Therefore, the ability to coat
these implanted devices to direct the molecular environment of this host cell/surface
interface becomes crucially important. Herein, we report the characteristics of a
polyelectrolyte multilayer nanolayered thin film able to deliver sufficient doses of a
therapeutic protein to direct the host cell response from virtually any surface, regardless of
geometry or surface chemistry, with release that is tunable and locally sustained.
Traditional covalent surface attachment strategies and bulk polymer release systems each
fail to reach the full potential of this surface modification strategy. The limited quantity
involved in direct surface attachment of proteins hampers achievable dose, and loss of
activity can result from the use of covalent linkages. Bulk polymer systems such as
polylactic acids or polycaprolactones are not as easily coated onto complex medical device
geometries in a conformal manner, and typically are prepared as blends with the polymer in
harsh solvents or at high temperatures that inactivate proteins. Surface release chemistries
and polymer breakdown products from more acidic polymer degradation products can yield
localized low pH conditions that further damage protein drugs [3].
Layer-by-Layer (LbL) assembly, in which a charged substrate is alternately dipped in
positively and negatively charged polymer baths to build a nanolayered thin film, has
recently been explored as a means of release of drugs of all kinds from surfaces [4–8]. LbL
is unique in its ability to sequester high concentrations of biologic drugs for controlled local
delivery using room temperature, mild aqueous conditions that preserve fragile protein
activity. Precise control can be exerted on the architecture of the film, allowing
compartmentalization and thus sequential release [9]; the drug load can be easily tuned with
the number of layers incorporated [10]. However, in the past, thin film methods in general
have been unable to achieve the microgram doses of biologics necessary for directing host
tissue response; in fact, for recently explored LbL systems, films have been unable to mount
a sufficient dose (usually nanogram quantities) or control over release to act as independent
localized therapeutic depots (e.g.,without co-implantation with stem cells) [11,12].
Herein, we characterize a LbL protein drug delivery system able to achieve multi-week,
microgram scale delivery of growth factors capable of directing in vivo host cell behavior.
Our approach is to use a tetralayer architecture utilizing 1) Poly2, a synthetic, intrinsically
tunable cationic polymer which is a poly(β-aminoester) [13,14], 2) a biological polyanion,
chondroitin sulfate, and 3) a growth factor of interest. Here we use Bone Morphogenetic
Protein 2 (BMP-2), a therapeutic protein known to be able to induce native progenitor cell
differentiation to the bone lineage. It is highly anticipated that local BMP-2 release from hip
implants will aid in tissue ingrowth onto implants, leading to more stable fixation and better
surgical outcomes [15]; ideally, release of such factors in sufficient quantity can lead to
recruitment of progenitor cells within the body without the need to introduce cultured stem
cells upon implantation. Poly2 is a member of the family of poly (β-aminoester)s (PBAEs),
which are hydrolytically degradable through the ester linkage and have been extensively
studied in gene therapy, tissue engineering, and have been shown to exhibit sequential
delivery applications from multilayer films with appropriate architectures [9,13]. Here, LbL
was used to conformally coat the complex geometries of a 3-dimensionally printed β-
tricalcium phosphate/polycaprolactone (3DP βTCP/PCL) scaffold to induce bone formation
on an implanted surface that would otherwise be unable to direct such a biological response.
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2. Materials and Methods
2.1 Materials
Chondroitin sulfate sodium salt (Mn = 60000) was obtained from VWR Scientific (Edison
NJ). Poly (β-aminoester) 2, hereafter called Poly 2, was synthesized as previously described
[14]. Recombinant human BMP-2 (rhBMP-2) was obtained from Insight Genomics (Falls
Church, VA). BMP-2 ELISA kits were obtained from Peprotech (Rocky Hill, NJ). Sodium
acetate buffer, 3M was obtained from Sigma Aldrich (St. Louis, MO).
2.2 Preparation of polyelectrolyte solutions
Poly 2 dipping solutions were 2 mg/mL in 25 mM sodium acetate buffer, pH 5.1.
Chondroitin dipping solution consisted of 2 mg/mL chondroitin in deionized water (18.2
M3, Milli-Q Ultrapure Water System, Millipore). rhBMP-2 dipping solutions were 50 ug/
mL in 100 mM sodium acetate buffer, pH 5.1. Poly 2 and chondroitin dipping solutions
were replaced and an additional 50 ug/mL of BMP-2 was added to the pre-existing bath,
every 24 hours. All wash baths were deionized water.
2.3 Film construction and characterization
Therics™ polycaprolactone/β-tricalcium phosphate (PCL/BTCP) co-polymer blend 3D
printed scaffolds were plasma etched with room air using a Harrick PDC-32G plasma
cleaner on high RF power for 1 minute and immediately immersed in Poly2 solution. A
nanolayerd film was fabricated on this scaffold with a Carl Zeiss HMS programmable slide
stainer with the following dipping protocol: 5 minutes in Poly 2 solution, 3 washes (10, 20,
30 s), 5 minutes in chondroitin solution, 3 washes (10, 20, 30 s), 10 minutes in BMP-2
solution, 1 wash (10s) and 5 minutes in chondroitin solution with 3 washes (10, 20, 30 s).
2.4 Release characterization
BMP-2 film coated scaffolds were released at 37ºC into 1 mL of growth medium, consisting
of αMEM supplemented with 10% fetal bovine serum and 1% penicillin streptomycin
(Invitrogen, Carlsbad CA). At a series of different time points, 0.5 mL of medium and eluted
material was removed and 0.5 mL of fresh release medium was replaced. Samples were
analyzed using ELISA development kits according to manufacturer instructions and cell
differentiation assays (see below).
2.5 Cell culture
MC3T3-E1 Subclone 4 (ATCC, Manassas, VA) were maintained in growth medium and
split when subconfluent. MC3T3-E1 cells were seeded at 1 × 104 cells/cm2 and allowed to
grow to confluence in 96 well plates (quantification) and in 8 well chamber slides
(visualization) in 100 uL of growth medium. MC3T3-E1 cells were cultured under four
experimental conditions: (1) growth medium, (2) differentiation medium (growth medium
supplemented with 50 μg/ml L-ascorbic acid and 10 mM β-glycerol phosphate), (3)
differentiation medium supplemented with 90 ng/mL of BMP-2, and (4) differentiation
medium supplemented with 90 ng/mL of PEM-released BMP-2. Cell culture media were
changed every two days until analysis for alkaline phosphatase, alizarin red, or Von Kossa
as described below.
2.6 Alkaline phosphatase activity assay
Alkaline phosphatase (ALP) activity was determined on day 6 after the initiation of MC3T3-
E1 osteogenic differentation by visual staining techniques and quantitation of the enzyme
activity. Cells were rinsed with PBS without Ca2+ and Mg+ and incubated in a stain solution
consisting of 50 mM Tris HCL pH 8.0 with 1 mg/mL fast red and 1% napthol AS-MS
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dissolved in DMSO for 30 minutes at 37ºC. An equal volume of 8% paraformaldehyde was
added for 10 minutes at room temperature to fix cells. After rinsing 2x with distilled water,
cells were imaged using a Zeiss inverted microscope with a 10X objective lens and Imaging
software. The stain was solublized by adding 0.1% triton in PBS and then freezing to −80ºC
for one freeze-thaw cycle. The cell lysates were transferred to an eppendorf tube,
centrifuged at 15,000g for 3 min at 4ºC, and the supernatant was collected. Fifty μL of lysate
was incubated with 150 μL of pNPP solution for 30 min at 37ºC. The reaction was
terminated with 0.1 M NaOH and ALP activity read on a plate reader at 405nm. The ALP
activity measurements were normalized to total protein determined by BCA assay.
2.7 Alizarin red S differentiation assays
After 28 days of exposure to differentiation medium, MC3T3-E1 cells were assayed for
calcium deposition using Alizarin red S (ARS). Cells were washed with PBS and fixed with
4% paraformaldehyde for 10 minutes. After three rinses of 5 min in distilled water, ARS
stain solution (2% ARS in distilled water pH balanced to 4.1 with 10% ammonium
hydroxide) was incubated with cells for 20 min at room temperature. Cells were then
washed in distilled water 4 times for 5 minutes each. The ARS stained cultures were imaged
with phase contrast microscopy.
The ARS stain was quantified using a previously published protocol [16]. The ARS stained
cultures were incubated in 10% acetic acid for 30 minutes at room temperature and then the
cell layers were disrupted by the use a pipette tip. The cell suspensions were transferred to a
microcentrifuge tube, vortexed for 30s, paraffin wrapped and heated at 85ºC for 10 min.
After transferring to ice for 5 min, the tubes were centrifuged at 16,000 g for 15 minutes and
pH balanced with 10% ammonium hydroxide to 4.1–4.5 pH units. Duplicates were read on a
96-well plate with black sides and a clear bottom at 405 nm.
2.8 Von Kossa differentiation assay
Von Kossa staining was performed to determine the presence of mineralization nodules
within the MC3T3-E1 cell cultures. Cultures were rinsed with PBS, fixed with 4% PFA for
10 minutes, and then washed in distilled water. The cultures were then incubated in a 3%
aqueous silver nitrate solution for 30 minutes at 37°C. The silver nitrate stained cultures
were then treated in a UV Stratalinker under UV light at 254 nm. The cultures were washed
with distilled water and then neutralized with 5% sodium thiosulfate for 5 minutes at room
temperature. A final wash with distilled water was performed and the cultures were imaged
by phase contrast microscopy.
2.9 Intramuscular bone formation model
All animal work was performed in accordance with protocols approved by the Committee on
Animal Care at the Massachusetts Institute of Technology. Sixteen 350–400 g male Sprague
Dawley rats were given preoperative analgesics (1mg/kg meloxicam and 0.05 mg/kg
buprenex), and intraoperative anesthesia via 1–3% isoflurane in oxygen. The right hindlimb
of each animal was shaved, cleaned with alcohol and povidone iodine solutions, and sterile
drapes were placed around the surgical area. A 2 cm longitudinal incision, centered at the
midshaft of the femur, was made laterally along the hindlimb. A pocket made in the
quadriceps muscle mass by blunt dissection anterior to the iliotibial band. One LbL-coated
PCL/BTCP scaffold was inserted into the intramuscular pocket, and wounds were closed
progressively with three layers of sutures (muscle, subcutaneous, and dermal layers). Each
hindlimb was implanted with either a control scaffold, [P2/chondroitin sulfate]200, or a
BMP-2 scaffold, [P2/chondroitin sulfate/rhBMP-2/chondroitin sulfate]100. Postoperatively,
rats were treated with buprenex and meloxicam until signs of distress dissipated. Rats were
housed in separate cages with free access to food and water. At four and eight week time
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points, four rats implanted with the control scaffold and four rats implanted with the BMP-2
scaffold were sacrificed and the implants retrieved for analysis as described below.
2.10 Micro-computed tomography (MicroCT) analysis
Excised samples were immediately placed in 10% neutral buffered formalin and imaged
with MicroCT (eXplore Locus, GE Medical Systems, London, Ontario) at a resolution of 27
μm with proprietary software included with the system (EVS Evolver, GE Medical Systems,
Fairfield, CT). The scanning protocol was performed with a 2000 ms shutter speed, 1×1 bin
size, at X-ray tube parameters 80kV and 450 μA. Four hundred images were taken at
incremental angles, and rendered 3D images were reconstructed with the Reconstruction
Utility and analyzed using MicroView (GE Healthcare, Fairfield, CT). Threshold values
were chosen by visual inspection and kept constant across 1 month or 2 month data sets.
Three independent regions of interest (ROIs) were chosen per sample, and the bone analysis
tool was used to measure bone mineral density and stereology measurements of each
sample. Three dimensional representations of bone formation and two dimensional digital
slices through the samples were also taken for qualitative comparison.
2.11 Histological analysis
After 24 hours in 10% formalin, tissues were transferred to solutions of 70% ethanol prior to
decalcification. Tissues were decalcified for 5 days in a solution of 15% EDTA and 10%
sodium citrate buffer, pH 7.2 at 4ºC under continuous stirring. Tissues were then serially
sectioned, routinely processed, and embedded in paraffin. Microscope sections (4 μm) were
stained with hematoxylin and eosin (H&E), Alcian Blue, and Masson’s trichrome stains.
3. Results and Discussion
BMP-2 has an isoelectric point of 8.5, a molecular weight of 32 kDa, and is a positively
charged protein under the LbL dipping conditions described herein (pH 5.1). The poly(β-
aminoester)s also exhibit positive charge due to the amine groups along the backbone [17].
Hence,a tetralayer architecture was required to incorporate both cationic molecules into an
electrostatically driven LbL multilayer thin film. In previous work with the model protein
lysozyme, which has similar molecular weight and isoelectric point to BMP-2 [6], the
natural polyanion chondroitin sulfate has been shown to have excellent electrostatic binding
properties, as well as desirable protein loading and release characteristics and retention of
bioactivity in LbL films. We therefore used chondroitin sulfate to create tetralayers with the
following architecture (Figure 1): [Poly2/chondroitin sulfate/BMP-2/chondroitin sulfate]n,
where the term in brackets represents the architecture of one tetralayer repeat unit and n
denotes the number of tetralayer units deposited.
Of the family of poly(β-aminoester)s available, Poly2 (Figure 2, structure) was chosen (i)
because it affords all of the positive characteristics of this class of polymers, including
biocompatibility, ease of manufacture, hydrolytic degradation, and positive charge, while
(ii) additionally providing a more sustained release profile compared to other polymers [6].
The prolonged half-life of Poly2 is due to the presence of a hydrophobic region near the
ester bond and a consequent decrease in water attack on the bond, hence a slower
degradation rate of the polymer. In previous work, we have shown that the advantageous
characteristics of an increased hydrophobic region on delaying degradation were found to
balance with a point in which the polymer no longer had sufficient ionic cross-links to avoid
bulk release [18]; Poly2 therefore balances increased release time with enough electrostatic
backbone charge to generate very stable electrostatic LbL films.
Macdonald et al. Page 5
Biomaterials. Author manuscript; available in PMC 2012 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
In Figure 3, the film growth of [P2/chondroitin/BMP-2/chondroitin] films deposited on
planar substrates is confirmed using profilometry measurements of film thickness. This
formulation exhibits a classic multilayer exponential buildup behavior (R2 = 0.96), with
each tetralayer incorporating more material than the last. An exponential building behavior
indicates that an interdiffusive process is taking place in which polymers adsorb to the top of
the film while also penetrating into the bulk of the built film [19–22]. This type of building
behavior is most frequently seen in biological systems where the charge density along the
polymer backbone is lower, leading to a lower ionic crosslink density and a loopier polymer
architecture [6], or in the case of small molecules which have fewer electrostatic interactions
to break and therefore diffuse more readily [8,23]. It is hypothesized that the dip time and
the diffusivity of the polymer lead to one region at the top of the film under constant
rearrangement with each dip bath; underneath is a reorganized region that is inaccessible to
polymer diffusion due to the short periods of dipping. At 2–3 microns for a 100 tetralayer
film, the LbL films discussed in this paper are much thicker than the typical LbL multilayer
film. These LbL films therefore have the unique advantage of an effective reservoir large
enough to allow significant drug encapsulation. However, this LbL coating remains orders
of magnitude thinner than traditional bulk degradation polymer delivery models [24,25]
(that are typically millimeter to sub-millimeter in scale) and is conformal to the coated
surface, allowing applicability to a wide variety of existing implant technologies.
A three dimensional, porous scaffold was used for in vitro and in vivo testing as a model
implant. A macroporous scaffold made of osteoconductive, biocompatible elements was
chosen for the following three reasons: (i) total drug load scales with film surface area,
allowing for a greater load per volume in a macroporous three dimensional substrate
compared with a flat film; (ii) such a functionalized, combination osteoconductive/
osteoconductive scaffold is of interest by itself if biologic molecules can be applied to it in a
way that increases bone formation for critical sized defects or when not enough autografted
bone can be harvested; (iii) typically both an osteoinductive agent, such as BMP-2, and an
osteoconductive microenvironment are necessary for ectopic bone formation. In the 3D-
printed (3DP) β-tricalcium phosphate/polycaprolactone scaffolds used for this work, a
precisely defined architecture can be employed, while taking advantage of the
biocompatibility and bioactivity of the polymer material blend, allowing for a reasonable
test substrate. It should be noted that these LbL coatings present a platform technology that
can be applied to a very broad range of scaffold materials, devices or implant surfaces that
have been optimized for specific applications.
Scaffold film coverage was probed using a fluorescent model protein, lysozyme (a model
protein with similar isoelectric point and molecular weight to BMP-2) labeled with Alexa
Fluor 488. Conformal surface coverage of the morphology of the 3DP scaffold (Figure 4)
can be seen by visualizing the fluorescent LbL layer on top. 3D reconstruction assimilating
all of the planes of focus shows a smooth coating in which the LbL film takes on the shape
of the underlying popcorn-like scaffold surface.
[P2/chondroitin/BMP-2/chondroitin]100 films constructed on the 3DP scaffolds show a
distinct two-regime release profile (Figure 5). Very little burst release is seen from the film;
compared with known clinical bulk collagen carriers and depots in which 40–60% of the
encapsulated protein is immediately released in the first 3 hours with low therapeutic effect
[26], here control over release leads to only 1% release in the same period, allowing the
sustained release and interaction necessary to achieve bone development. A sustained linear
release profile is observed for the first two days (R2 = 0.9848) in which 80% of the film
contents are released. The release profile then shifts to a second regime which is well fit to
both linear (R2 = 0.96) and power law (R2 =0.997) equations, in which the additional 20%
of film release is sustained over an additional 2 weeks. A typical coated 3DP scaffold used
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for in vitro and in vivo tests weighed 14 mg and released 10.6 +/− 0.3 ug of total BMP-2
from the scaffold surface. The quantities released are on par with successful in vivo bulk
release approaches, such as the collagen sponge, but the volumetric loading density of our
LbL film (10 μg BMP-2/mm3), is three orders of magnitude higher than typical bulk
releasing films[24,25]. It is interesting to note that BMP-2 release can be controlled and
sustained, even from such an ultrathin LbL coating.
To test for bioactivity of the coatings, MC3T3 E1 Subclone 4 pre-osteoblasts were exposed
to (i) M - their normal growth medium (ii) D - growth medium plus β glycerol phosphate
and L-ascorbic acid (differentiation medium) (iii) B - (D) with 90 ng/mL BMP-2 from stock,
or (iv) R - (D) with 90 ng/mL BMP-2 released from an LbL film. Alkaline phosphatase (AP)
serves as a standard early marker of induction of new bone differentiation from progenitor
cells. In Figure 6, AP is markedly increased by BMP-2 LbL films compared with control
films. Furthermore, cultures which have been induced to bone differentiation are able to
form calcium deposition in the extracellular matrix (Alizarin Red staining) upon maturation,
in addition to mineralization of the calcium deposits by incorporation of phosphate ions
(Von Kossa staining). In Figure 6, staining of Alizarin Red and Von Kossa confirm
osteoblast differentiation to a mature bone phenotype from BMP-2 exposure.
This result can also be quantified in the case of AP and Alizarin Red using
spectrophotometric tests [16]. Interestingly, quantification for each data set (right hand
panel) suggests that BMP-2 released from the LbL films shows increased gene induction
and resulting differentiation within statistical significance (ANOVA analysis) compared to
matched concentrations of BMP-2 supplemented directly to the medium. We hypothesize
that the effective BMP-2 concentration perceived by the cells was increased due to the
presence of Poly2 and chondroitin sulfate in the LbL release solution, possibly due to
synergistic complexation of the biopolymer with sites on the BMP-2 protein and on the cell
membrane surface. Thus, bioactivity of BMP-2 incorporated and released from LbL films
remains intact.
We next turned to in vivo assays to probe whether the retained BMP-2 activity was robust
enough to induce native host progenitor cells to initiate the bone differentiation cascade,
creating bone in an intramuscular site. LbL coated scaffolds with or without incorporated
BMP-2 were implanted in the rat quadriceps muscle (1 scaffold per animal). Micro
computed tomography (MicroCT) images at four and nine week time points show large bone
deposits created in response to BMP-2 LbL films. BMP-2 LbL implants (Figure 7, left)
show new plate-like bone trabeculi that progressively increase in thickness from four to nine
weeks. The bone forms with pattern fidelity to the underlying scaffold (central panels),
underscoring the importance of the LbL slow-release carrier and BMP-2 surface
concentration to bone formation, and new bone continued to be deposited even at 9 weeks.
In contrast, no bone was formed in scaffolds coated with LbL films lacking BMP-2 (right
panels). Thus BMP-2 released from LbL films can precipitate host progenitor cell induction
to bone tissue. Quantification of the MicroCT images demonstrate an increase in bone
mineral density (BMD) from four to nine weeks (right panel, Figure 7), consistent with
continued maturation to more mineral dense bone.
Histological evaluation from the in vivo experiments further confirms ongoing, active
deposition of mineralized bone matrix (Figure 8). Copious bone is found in full-thickness
sections of BMP-2 releasing scaffolds at nine weeks; no bone was found in controls (Figure
8A & B). In LbL BMP-2 sections, cell types associated with healthy tissue remodelling
dominate. The bone contains embedded osteocytes, osteoblasts lining the bone surface and
laying down new bone, and cement lines from previous osteoblast expansions, consistent
with active bone remodelling (Figure 8C). Hence, cell-free BMP-2 LbL implants are capable
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of recruiting progenitor cells from the animal’s native tissue and inducing a desired tissue
response to implantation.
Bone maturation is also evident from histology. As bone matures, it goes from a woven,
unorganized collagen matrix structure to a lamellar structure with aligned collagen fibrils
that are birefringent under polarized light. The bone in Figure 8D and E has highly aligned
collagen fibrils that indicate mature bone. Adipocytes are present in areas of mature lamellar
bone, recapitulating the fatty marrow architecture and suggesting a high level of tissue
maturation. Interestingly, not only are existing bone deposits maturing, but ongoing
differentiation of host progenitor cells leads to new colonies of bone cells (Figure 8F). A
cartilage intermediate is visible in the tissue induced by LbL BMP-2 films (Figure 8G,H)
consistent with the anticipated endochondral bone formation process, in which cartilage is
progressively replaced with bone. The recapitulation of bone architecture, cell phenotypes,
placements, and the activation of further cell differentiation cascades, all precipitated by
LbL released BMP-2 from the scaffold surface, show the tremendous impact that this
technique can have on integration of implanted medical devices with surrounding tissue;
none of the aforementioned biological processes is present in LbL scaffolds lacking BMP-2.
4. Conclusions
Localized release of biologics from implantable medical devices represents a powerful tool
that can alter the course of healing and complications after implant deployment. As
demonstrated here, micron-scale coatings of growth factors can wholly change the
microenvironment to encourage bone tissue induction and in-growth to enhance integration
with the implanted device. Here we demonstrate LbL coatings with high loading capacity
that significantly exceeds typical biologic-encapsulating films, and capable of locally
delivering the necessary microgram quantities of active growth factor to direct the native
host cell response in a sustained manner as of yet unachievable with current depot devices.
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Figure 1.
Schematic of LbL architecture shows that a 3DP scaffold (or glass surface) is repeatedly
dipped with tetralayer units consisting of (1) Poly 2 (positively charged), (2) chondroitin
sulphate (negatively charged), (3) BMP-2 (positively charged) and (4) chondroitin sulfate.
This tetralayer structure is repeated 100 times for all LbL films in this communication.
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Figure 2.
Structure of Poly2, the selected poly(-aminoester) used in this work.
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Figure 3.
Profilometry measurements of LbL films built on glass allow for thickness analysis. Film
thickness grows exponentially (R2 = 0.96) with increasing numbers of tetralayers in a [P2/
Chondroitin/BMP-2/Chondroitin]n film.
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Figure 4.
A 3DP βTCP-PCL blend scaffold was dipped with [P2/chondroitin/fluorescent lysozyme/
chondroitin]100. A three dimensional reconstruction of the resulting fluorescent LbL film
shows a coating with conforms to the roughened, popcorn ball-like surface of the underlying
3DP scaffold.
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Figure 5.
Release of BMP-2 from LbL films built on 3DP scaffold. Eighty percent of the material is
released over a two day, linear release period. The remaining twenty percent is released over
a period of approximately two weeks. Inset shows a blow up of the release profile after the
initial two day period. Fourteen mg of scaffold were inserted in in vivo experiments; thus
approximately 10 ug of BMP-2 were released from scaffolds.
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Figure 6.
Left panel: Bioactive BMP-2 released from LbL films (sample R) induces differentiation of
MC3T3 pre-osteoblasts to an osteoblast phenotype compared with differentiation medium
alone (sample D). Alkaline Phosphatase (ALP) staining (red) shows early (day 6) activation
of the bone differentiation cascade; At 28 days of culture Alizarin Red staining for calcium
deposition (red), and Von Kossa staining for mineralization of the calcium matrix (black)
confirm the differentiation process to osteoblasts. Right panel: Quantification of the staining
signal (3 readings on four independent experiments; error bar is standard deviation) shows
that the increase in activity of BMP-2 released from LbL films (R) over BMP-2 positive
control (B)(matched 90 ng/mL for both samples) is statistically significant. A single factor
ANOVA test allowed rejection of the null hypothesis for both assays; a Tukey test showed
that B and R are statistically different with p<0.01 for ALP assay. Both B and R outperform
differentiation medium alone (D) or growth medium alone(M). GM = growth medium; L+β
= L-ascorbic acid and β-glycerol phosphate (differentiation factors); F BMP = LbL Film-
released BMP-2; BMP = BMP-2 added directly to the medium.
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Figure 7.
Host progenitor cells exposed to LbL BMP-2 films undergo bone induction, creating
calcium deposits visible with microCT in an intramuscular site. MicroCT 2-dimensional
slices through the implant (top left panels) show that bone plate thickness is increasing with
time; three-dimensional reconstructions (top middle panels) show remarkable pattern fidelity
to the underlying scaffold, suggesting that bone grows in an outward-radiating pattern.
Control films lacking BMP-2 show very little radio opacity (top right panels) indicating that
BMP-2 is necessary for bone induction; three-dimensional images could not be
reconstructed. In the bottom graph, bone mineral density, a marker of bone maturity,
increases with implant age, indicating continual remodelling and maturing within the bone
tissue. Scalebars are 4 mm.
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Figure 8.
Histologic findings from in vivo studies.. (A and B) Active scaffolds coated with BMP-2,
Poly2, chondroitin sulfate film (A) and control scaffolds coated with Poly2 and chondroitin
sulfate film (B), both at 9 weeks post-implantation. Brilliant blue staining of lamellar bone is
seen in the active, but not control scaffolds (Masson trichrome stain, 40× original
magnification). (C) Lamellar bone showing active bone formation with osteoblasts (blue
arrows), mature osteocytes in lacunae (white asterisks) and cement line (white arrow) in
active scaffolds at 9 weeks post-implantation. (H&E staining, 400× original magnification).
(D and E) Mature lamellar bone with fatty marrow space (asterisk) under normal (D) and
polarized light microscopy (E) at 9 weeks post-implantation. Note the bright signal from
parallel collagen fibers indicating highly aligned lamellar bone, especially between the white
lines. (H&E staining, 100× original magnification) (F) Woven bone formation (arrow) seen
as a focus with pale blue staining and higher cellularity (black arrow) in contrast to the
mature lamellar bone just below at 4 weeks post-implantation (Masson trichrome stain, 100×
original magnification). (G and H) Cartilaginous intermediate areas (blue staining in G) are
being remodeled into mature bone at 4 weeks post-implantation. The more mature areas
brightly polarize while the immature cartilaginous areas do not (in H) (Alcian blue staining,
200× original magnification).
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